Development of shellfish allergy after exposure to dual immune checkpoint blockade

Autor:	Zachary J Brown, Bernd Heinrich, Tim F Greten
Jazyk:	angličtina
Rok vydání:	2018
Předmět:	allergy checkpoint inhibitors durvalumab hepatocellular carcinoma immunotherapy tremelimumab Diseases of the digestive system. Gastroenterology RC799-869 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Hepatic Oncology, Vol 5, Iss 1 (2018)
Druh dokumentu:	article
ISSN:	2045-0931 2045-0923
DOI:	10.2217/hep-2017-0021
Popis:	Hepatocellular carcinoma (HCC) is a major health problem worldwide with limited systemic therapies available. Immunotherapy is a fast-moving field that is quickly evolving as a treatment for HCC with three recent clinical trials published treating HCC with immune checkpoint inhibitors with promising results. Checkpoint inhibition may lead to a unique adverse event profile with the potential to cause immune-related adverse events by unbalancing the immune system. Here, we report a case of a 61-year-old male with advanced HCC who developed a shellfish allergy after completing three cycles of combination of tremelimumab and durvalumab therapy.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/8218a6d9bcb34f1e8a0e05323e9241fc Zobrazit plný text záznamu View record in DOAJ